相关实验视频

Updated: Jul 8, 2025

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

502

向PKC可以减轻糖尿病和血色素变异症中铁过载

Somesh Banerjee, Shaolei Lu, Anand Jain

    bioRxiv : the preprint server for biology
    |December 11, 2023
    PubMed
    概括

    糖尿病可以通过增加ferroportin (Fpn) 表达来加剧铁过载,这是由蛋白激酶C (PKC) 调节的过程. 抑制PKC有助于控制糖尿病和血液染色病中的铁含量.

    更多相关视频

    Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes15:43

    Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

    Published on: January 7, 2013

    18.2K
    Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

    Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

    Published on: March 14, 2017

    19.5K

    相关概念视频

    iPS Cell Differentiation01:22

    iPS Cell Differentiation

    The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
    2.7K
    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    174